Search





Search





Markets
/
Stocks
/
nasdaq-dxcm
/

Dexcom Inc

DXCM

Add to Watchlist

60.833USD

-0.307-0.50%

Market hours （ET）Quotes delayed by 15 min

23.48BMarket Cap

25.43P/E TTM



Dexcom Inc

60.833

-0.307-0.50%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Dexcom Inc

Currency: USD Updated: 2026-05-12

Key Insights

Dexcom Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 84.82.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dexcom Inc's Score

Industry at a Glance

Industry Ranking

41 / 206

Overall Ranking

132 / 4490

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Dexcom Inc Highlights

StrengthsRisks

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 28.70% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.66B.

Undervalued

The company’s latest PE is 25.56, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 384.48M shares, decreasing 5.90% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 4.68K shares of this stock.

Analyst Rating

Based on 31 analysts

Buy

Current Rating

84.821

Target Price

+39.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-12

The current financial score of Dexcom Inc is 8.64, ranking 22 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 1.19B, representing a year-over-year increase of 15.05%, while its net profit experienced a year-over-year increase of 89.28%.

Score

Industry at a Glance

Previous score

8.64

Change



Financials

8.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.76

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.67

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Dexcom Inc's Company Valuation

Currency: USD Updated: 2026-05-12

The current valuation score of Dexcom Inc is 3.97, ranking 195 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 25.56, which is 581.71% below the recent high of 174.26 and 2.96% above the recent low of 24.81.

Score

Industry at a Glance

Previous score

3.97

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 41/206

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-12

The current earnings forecast score of Dexcom Inc is 8.52, ranking 25 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 84.20, with a high of 112.00 and a low of 68.00.

Score

Industry at a Glance

Previous score

8.52

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 31 analysts

Buy

Current Rating

84.821

Target Price

+39.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

116

Total

Median

Average

Company name

Ratings

Analysts

Dexcom Inc

DXCM

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Medline Ord Shs Class A

MDLN

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-12

The current price momentum score of Dexcom Inc is 6.94, ranking 88 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 65.38 and the support level at 56.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.63

Change

0.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.383

Neutral

RSI(14)

47.649

Neutral

STOCH(KDJ)(9,3,3)

59.747

Neutral

ATR(14)

2.173

High Vlolatility

CCI(14)

22.290

Neutral

Williams %R

37.394

Buy

TRIX(12,20)

-0.292

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

60.470

Buy

MA10

60.033

Buy

MA20

61.135

Sell

MA50

64.005

Sell

MA100

67.110

Sell

MA200

68.607

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Dexcom Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 99.64%, representing a quarter-over-quarter decrease of 4.13%. The largest institutional shareholder is Baillie Gifford, holding a total of 15.60M shares, representing 4.04% of shares outstanding, with 11.79% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

24.63M

+1.26%

State Street Investment Management (US)

18.09M

+7.35%

Baillie Gifford & Co.

Star Investors

15.55M

-2.08%

Geode Capital Management, L.L.C.

11.01M

+0.39%

AllianceBernstein L.P.

8.62M

+1955.43%

Invesco Capital Management (QQQ Trust)

8.29M

-2.43%

Norges Bank Investment Management (NBIM)

7.28M

+40.25%

BlackRock Financial Management, Inc.

5.43M

+12.54%

Risk Assessment

Currency: USD Updated: 2026-05-12

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dexcom Inc is 6.55, ranking 56 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.